YieldMax AMZN Option Income Strategy ETF vs ARK Genomic Revolution ETF — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.3, while ARK Genomic Revolution ETF trades at $44.56. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | ARKG | |
|---|---|---|
Sector | Income / Options Overlay | Sector/Thematic |
52-Week High | $15.75 | $44.55 |
52-Week Low | $9.98 | $24.02 |
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.29, down 2.84% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides weekly dividend distributions, with recent payouts ranging from $0.06 to $0.14, supporting high yield but raising sustainability concerns. Key support is at $11, with resistance at $12, as the RSI indicates potential overbought conditions near-term.
The outlook for AMZY hinges on its ability to maintain high dividend yields without eroding net asset value. Risks include NAV erosion from its synthetic option strategy and underperformance versus Amazon stock. Analyst sentiment is cautious due to structural drawbacks, making it suitable only for income-focused investors aware of the trade-offs.
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
Trailing returns across standard periods
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →